Therapeutic antibodies for the prevention and treatment of cancer

Related Experiment Video

Updated: Jul 5, 2025

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
08:53

In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research

Published on: September 16, 2019

9.0K

Mukesh Kumar1, Akansha Jalota2, Sushil Kumar Sahu3

  • 1Department of Medical Oncology, Thomas Jefferson University, Philadelphia, PA, 19107, USA. mraj03@gmail.com.

Journal of Biomedical Science
|January 12, 2024
PubMed

Insights

Antibodies are successful cancer therapeutics, but resistance necessitates combination therapy. This review explores antibody efficacy, resistance mechanisms, and FDA-approved examples for improved patient care.

Area of Science:

  • Oncology
  • Immunology
  • Pharmacology

Background:

  • Antibody therapeutics have shown significant success in cancer treatment.
  • Factors like antibody origin, isotype, affinity, and mechanism of action influence therapeutic efficacy.
  • Recombinant antibody formats are crucial for immune cell manipulation in cancer therapy.

Purpose of the Study:

  • To review the multifaceted aspects of antibodies in cancer therapy.
  • To discuss factors affecting antibody efficacy and mechanisms of therapeutic resistance.
  • To provide examples of US FDA-approved antibodies for cancer treatment.

Main Methods:

  • Literature review of antibody development in cancer therapeutics.
  • Analysis of antibody properties influencing efficacy (origin, isotype, affinity, avidity, mechanism of action).
  • Discussion of therapeutic resistance mechanisms and combination therapy strategies.

Main Results:

  • Antibodies offer targeted cancer treatment with fewer side effects than traditional chemotherapy.
  • Therapeutic resistance against antibodies is a growing challenge in patient care.
  • Combination therapy is emerging as a key strategy to overcome resistance.

Conclusions:

  • Antibodies are vital tools in modern oncology, but their effectiveness is challenged by resistance.
  • Understanding antibody-related efficacy and resistance is crucial for optimizing cancer treatment.
  • Combination strategies involving antibodies hold promise for improved patient outcomes.
Keywords:
AntibodyAntibody–drug conjugate (ADC)Cancer therapyChemo-resistanceImmune-modulation

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

5.3K
Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery13:19

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

2.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.6K
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
368
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
527
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
139